Key Sessions
Nelly Viseux
Keynote: Journey from R&D to Clinical Manufacturing
Regeneron
Robert Hofmeister
Keynote: Programming Immunity In Vivo: Targeted RNA-LNP Platforms for Precision CAR Engineering
CREATE Medicines
Silviu Itescu
Keynote Presentation: Lessons Learnt of the Path to Commercialisation
Mesoblast
Therese Choquette
Panel Discussion: Decentralized Manufacturing in Cell Therapy: Overcoming Implementation Challenges and Enhancing Patient-Centric Solutions
Tigen Pharma SA
Friday 25th September - Conference Day Three - ET (Eastern Time, GMT-05:00)
Friday 25th September - Conference Day Three - ET (Eastern Time, GMT-05:00)
8:25am - 8:50am25 mins
Registration Break
Registration & Morning Coffee
8:50am - 9:00am10 mins
Development of Emerging Cell & Gene Therapies
Chairperson’s Opening Remarks: Development of Emerging Cell & Gene Therapies
8:50am - 9:00am10 mins
Cell Therapy Manufacturing & Analytics
Chairperson’s Opening Remarks: Cell Therapy Manufacturing & Analytics
8:50am - 9:00am10 mins
Gene Therapy Manufacturing & Analytics
Chairperson’s Opening Remarks: Gene Therapy Manufacturing & Analytics
9:00am - 9:30am30 mins
Development of Emerging Cell & Gene Therapies
Keynote: Journey from R&D to Clinical Manufacturing
- Nelly Viseux - Vice President, Cell Therapies Development, Manufacturing, Supply & Quality, Regeneron
9:00am - 9:30am30 mins
Cell Therapy Manufacturing & Analytics
Panel Discussion: Decentralized Manufacturing in Cell Therapy: Overcoming Implementation Challenges and Enhancing Patient-Centric Solutions
- Therese Choquette - Chief Technical Officer, Tigen Pharma SA
- Thorsten Gorba - VP, Process & Analytical Development, Aspen Neuroscience, Inc.
- Tatyana Matveeva - Director of cGMP Operations, Regenerative Cell Therapy, Massachusetts General Hospital and Harvard Medical School
9:00am - 9:30am30 mins
Gene Therapy Manufacturing & Analytics
Keynote Panel Discussion: Navigating BLA Success - Strategies for Streamlined Gene Therapy Approval Success
- Tiffany D Rau, PhD - Principal Consultant BioPharma Technical Consulting and Rau Consulting, Adjunct Professor Biochemistry and Cell Biology, University College Cork, Ireland
9:30am - 10:00am30 mins
Development of Emerging Cell & Gene Therapies
Keynote: Programming Immunity In Vivo: Targeted RNA-LNP Platforms for Precision CAR Engineering
- Robert Hofmeister - Chief Scientific Officer, CREATE Medicines
9:30am - 10:00am30 mins
Cell Therapy Manufacturing & Analytics
Enabling sgRNA Release and Stability Testing with a ddPCR-Based Potency Assay
- Hugh Gannon - Associate Director, KSQ Therapeutics
9:30am - 10:00am30 mins
Gene Therapy Manufacturing & Analytics
From Vial to Brain: Demonstrating AAV Gene Therapy Stability During Convection-Enhanced Delivery
- Nathalie Clement - SVP, Vector Development, Siren Biotechnology
10:00am - 10:30am30 mins
Development of Emerging Cell & Gene Therapies
Moving Gene Editing Beyond the Liver
- Devyn M. Smith - Chief Executive Officer, Arbor Biotechnologies
10:00am - 10:30am30 mins
Cell Therapy Manufacturing & Analytics
Sponsored Scientific Track Presentation: Application and Validation of Rapid Cell Analytical Technologies for Product Release at Scale
10:00am - 10:30am30 mins
Gene Therapy Manufacturing & Analytics
Sponsored Scientific Track Presentation
10:30am - 11:15am45 mins
Break
Networking Refreshment Break in the Exhibit Hall
11:15am - 11:30am15 mins
Development of Emerging Cell & Gene Therapies
Development of Next Generation Cell Therapies for Autoimmune Disease
- Mayo Pujols - CTO, Kyverna
11:15am - 11:45am30 mins
Cell Therapy Manufacturing & Analytics
Culture and Non-Culture-Based Approaches to Cell Therapy Potency
- Ronnie Lum - Director Analytical Development, Analytical and Quality Control, BlueRock Therapeutics
11:15am - 11:45am30 mins
Gene Therapy Manufacturing & Analytics
Characterizing Adeno-associated viruses (AAV) by Micro-Electrophoresis
- Rishi Kothari - Process Development Engineer, Regeneron Pharmaceuticals
11:30am - 11:45am15 mins
Development of Emerging Cell & Gene Therapies
The Siren Experience: Advancing SRN-101 for High Grade Gliomas
- Lauren Kelly - Director of Translational Research, Siren Biotechnology
11:45am - 12:00pm15 mins
Development of Emerging Cell & Gene Therapies
Gene Therapy for Immune Reprogramming and the Treatment of Inflammatory Diseases
- Shahrooz Rabizadeh - CEO & Co-Founder, Sagittarius Bio, Inc
11:45am - 12:15pm30 mins
Cell Therapy Manufacturing & Analytics
Progress toward Standards and Reference Materials for Cell Viability
- Laura Pierce - Biomedical Engineer, NIST
11:45am - 12:15pm30 mins
Gene Therapy Manufacturing & Analytics
Machine Learning and Mechanistic Modeling Approaches Within Upstream Process Development to Improve AAV Product Quality
- Neil Templeton - Director, Upstream Process Development, Solid Biosciences
12:00pm - 12:15pm15 mins
Development of Emerging Cell & Gene Therapies
Case Studies: Development of Next-Gen Cell & Gene Therapies - Overcoming Challenges and Breakthroughs
12:15pm - 12:45pm30 mins
Development of Emerging Cell & Gene Therapies
Sponsored Scientific Track Presentation
12:15pm - 12:45pm30 mins
Cell Therapy Manufacturing & Analytics
Sponsored Scientific Track Presentation: Latest Advances in Cryopreservation Techniques and Maintaining Cell Viability at Scale
12:15pm - 12:35pm20 mins
Gene Therapy Manufacturing & Analytics
Predictive Modeling and Process Interdependency: A Strategic Approach to Late-Stage AAV Purification Development
- Chen Wang - Principal Scientist, GMU CMC Purification Process Development, Sanofi
12:45pm - 2:00pm75 mins
Break
Lunch in the Exhibit Hall (Last Chance to Meet with Exhibitors)
2:00pm - 2:05pm5 mins
Keynote Plenary
Chairperson’s Opening Remarks
2:05pm - 2:45pm40 mins
Keynote Plenary
Keynote Patient Fire Side Chat: Amplifying Patient Voices- Patient Centric CGT Innovation
2:45pm - 3:30pm45 mins
Keynote Plenary
Keynote Presentation: Lessons Learnt of the Path to Commercialisation
- Silviu Itescu - CEO, Mesoblast
3:30pm - 3:35pm5 mins
Close of Event 2026 - See You Next Year!
* 不測の事態により、事前の予告なしにプログラムが変更される場合があります。